title: Reply to S. Debska-Szmich et al.
authors: University Hospitals Leuven and KU Leuven, Leuven, Belgium eric.vancutsem@uzleuven.be.
authors: Eric
authors: E
authors: Van Cutsem
authors: Merck KGaA, Darmstadt, Germany.
authors: Frank
authors: F
authors: Beier
authors: Second University of Naples, Naples, Italy.
authors: Fortunato
authors: F
authors: Ciardiello
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D009154:Mutation; D018631:ras Proteins / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D018631:ras Proteins